VAM
CYTK icon

Visium Asset Management’s Cytokinetics CYTK Stock Holding History

Visium Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-400,000
Closed -$3.8M – 1121
2014
Q1 		$3.8M Buy
+400,000
New +$3.62M 0.06% 279

Other funds holding CYTK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LPU
Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
IIM
Ironwood Investment Management Boston, Massachusetts $240M AUM 45.82% 1-Year Est. Return

Visium Asset Management's CYTK Position: Q2 2014 in Review

Visium Asset Management sold out of Cytokinetics (CYTK) in Q2 2014, closing a stake of 550,200 shares — an estimated $5.23M sold.

Visium Asset Management first reported a position in CYTK in Q3 2013 and held it in 3 quarters. The position peaked at $5.23M in Q1 2014. 89 funds tracked by Wall St. Rank hold CYTK as of Q2 2014.

  • Visium Asset Management reported no remaining Cytokinetics position as of Q2 2014 after selling out during the quarter.
  • Visium Asset Management sold 550,200 Cytokinetics shares in Q2 2014, an estimated $5.23M.
  • Visium Asset Management first reported a position in Cytokinetics in Q3 2013 and held it in 3 quarters.
  • Visium Asset Management's Cytokinetics position peaked at $5.23M in Q1 2014.
  • 89 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2014.

Based on Visium Asset Management's 13F filing for Q2 2014, filed 14 Aug 2014.